20-Year Follow-Up to Clinical Trial Examines Risks of Recurrence

20-Year Follow-Up to Clinical Trial Examines Risks of Recurrence
The presence of ductal carcinoma in situ (DCIS), the most common type of non-invasive breast cancer, and young age are associated with increased risk of tumor recurrence on the same side of the body after treatment with breast-conserving therapy, according to a long-term follow-up of the EORTC “boost no boost” clinical trial. The European Organisation for Research

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *